Adicet Bio, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-26$8.70 RISE2026-05-19$7.25 PEAK2026-05-29$9.31 123d | -16.7% 113d | Missed | Missed | — | — | +28.4% 10d | Missed |
DROP2025-11-28$10.37 RISE2026-03-30$6.11 PEAK2026-05-29$9.31 182d | -41.1% 122d | Missed | Missed | — | — | +52.4% 60d | Missed |
DROP2025-10-16$16.64 RISE2026-02-05$6.44 PEAK2026-04-20$8.67 186d | -61.3% 112d | Missed | Missed | — | — | +34.6% 74d | Missed |
DROP2025-10-16$16.64 RISE2025-12-16$7.44 PEAK2026-01-02$8.82 78d | -55.3% 61d | Missed | Missed | — | — | +18.5% 17d | Missed |
DROP2025-06-10$13.12 RISE2025-08-11$9.54 PEAK2025-10-16$16.64 128d | -27.3% 62d | Missed | Missed | — | — | +74.5% 66d | Missed |
DROP2025-02-24$14.80 RISE2025-07-03$9.71 PEAK2025-09-11$14.11 199d | -34.4% 129d | Missed | Missed | — | — | +45.3% 70d | Missed |
DROP2024-11-29$18.08 RISE2025-04-10$7.15 PEAK2025-06-10$13.12 193d | -60.4% 132d | Missed | Missed | — | — | +83.4% 61d | Missed |
DROP2024-08-21$25.12 RISE2024-12-19$13.76 PEAK2025-01-06$17.44 138d | -45.2% 120d | Missed | Missed | — | — | +26.7% 18d | Missed |
DROP2024-03-11$39.36 RISE2024-07-05$17.12 PEAK2024-07-29$26.08 140d | -56.5% 116d | Missed | Missed | — | — | +52.3% 24d | Missed |
DROP2024-01-09$55.20 RISE2024-03-18$31.20 PEAK2024-04-01$38.40 83d | -43.5% 69d | Missed | Missed | — | — | +23.1% 14d | Missed |
DROP2023-07-21$47.04 RISE2023-11-28$17.76 PEAK2024-01-09$55.20 172d | -62.2% 130d | Missed | Missed | — | — | +210.8% 42d | Missed |
DROP2023-02-17$135.04 RISE2023-06-27$34.08 PEAK2023-07-12$54.40 145d | -74.8% 130d | Missed | Missed | — | — | +59.6% 15d | Missed |
DROP2022-12-05$323.04 RISE2023-04-12$84.32 PEAK2023-05-15$114.08 161d | -73.9% 128d | Missed | Missed | — | — | +35.3% 33d | Missed |
DROP2022-11-11$340.32 RISE2023-01-09$122.08 PEAK2023-02-02$147.68 83d | -64.1% 59d | Missed | Missed | — | — | +21.0% 24d | Missed |
DROP2022-08-05$299.84 RISE2022-09-29$214.88 PEAK2022-11-11$340.32 98d | -28.3% 55d | Missed | Missed | — | — | +58.4% 43d | Missed |
1–15 / 26 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
The average of price targets set by Wall Street analysts indicates a potential upside of 319.6% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
REDWOOD CITY, Calif., May 14, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York.
REDWOOD CITY, Calif., May 13, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2026.
Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.88) per share which beat the analyst consensus estimate of $(3.21) by 41.43 percent. This is a 62.1 percent increase over losses of $(4.96) per share from the
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $50 to $27.
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $128 to $100.
REDWOOD CITY, Calif., March 12, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2025.
-SEC Filing
Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(2.94) per share which beat the analyst consensus estimate of $(3.10) by 5.04 percent. This is a 42.58 percent increase over losses of $(5.12) per share from the
REDWOOD CITY, Calif., January 30, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York.
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $9 to $50.
REDWOOD CITY, Calif., January 07, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2026.
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.
REDWOOD CITY, Calif., December 26, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share.
Shares of Adicet Bio are trading lower after the clinical stage biotechnology company announced a one-for-16 reverse stock split.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACET | +13.54% | +27.71% | +10.57% | -18.96% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +10.57% | +33.42% | +14.01% | -31.65% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 232.6K | $1.58M | 0.00% | Trimmed-4.3% | 2026-03-31 |
| TwoSigma | quant | 43.1K | $293.55K | 0.00% | Trimmed-70.2% | 2026-03-31 |
| StateStreet | passive | 36.2K | $246.67K | 0.00% | Added+39.9% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-29 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | J Other acquisition(deriv) | 250,000 | — | — |
| 2026-04-29 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | J Other acquisition | 250,000 | — | — |
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P Open-market purchase | 74,751 | $7.27 | +$543.4K |
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P Open-market purchase | 74,268 | $7.21 | +$535.5K |
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P Open-market purchase | 74,577 | $7.04 | +$525.0K |
| 2026-04-09 | ORBIMED ADVISORS LLC | 10% Owner | S Open-market sale | 40,416 | $6.52 | −$263.5K |
| 2026-04-09 | ORBIMED ADVISORS LLC | 10% Owner | S Open-market sale | 32,523 | $6.29 | −$204.6K |
| 2026-04-09 | ORBIMED ADVISORS LLC | 10% Owner | S Open-market sale | 2,400 | $6.38 | −$15.3K |
| 2026-04-09 | ORBIMED ADVISORS LLC | 10% Owner | S Open-market sale | 29,319 | $6.53 | −$191.5K |
| 2026-03-27 | Aftab Blake | Chief Scientific Officer | A Grant / award(deriv) | 72,555 | — | +$0 |
| 2026-03-27 | Healey Don | Chief Technology Officer | A Grant / award(deriv) | 43,361 | — | +$0 |
| 2026-03-27 | Maltzman Julia D. | Chief Medical Officer | A Grant / award(deriv) | 72,555 | — | +$0 |
| 2026-03-27 | Schor Chen | President & CEO | A Grant / award(deriv) | 468,555 | — | +$0 |
| 2026-03-27 | Harvey Brian Nicholas | Chief Financial Officer | A Grant / award(deriv) | 43,361 | — | +$0 |
| 2026-01-27 | Harvey Brian Nicholas | Chief Financial Officer | F Tax withholding | 546 | $8.44 | −$4.6K |
| 2026-01-27 | Schor Chen | President & CEO | F Tax withholding | 1,755 | $8.44 | −$14.8K |
| 2026-01-27 | Healey Don | Chief Technology Officer | F Tax withholding | 535 | $8.44 | −$4.5K |
| 2026-01-27 | Aftab Blake | Chief Scientific Officer | F Tax withholding | 535 | $8.44 | −$4.5K |
| 2025-10-10 | ORBIMED ADVISORS LLC | 10% Owner | P Open-market purchase | 3,500,000 | $1.00 | +$3.50M |
| 2025-10-10 | ORBIMED ADVISORS LLC | 10% Owner | P Open-market purchase | 1,500,000 | $1.00 | +$1.50M |
| 2025-06-13 | Sinclair Andrew | Director | A Grant / award(deriv) | 26,400 | — | +$0 |
| 2025-06-13 | Sinclair Andrew | Director | A Grant / award | 5,900 | — | +$0 |
| 2025-06-13 | Peng Katie | Director | A Grant / award(deriv) | 26,400 | — | +$0 |
| 2025-06-13 | Peng Katie | Director | A Grant / award | 5,900 | — | +$0 |
| 2025-06-13 | DUBIN STEVE | Director | A Grant / award(deriv) | 26,400 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -1.64 | — | — |
| 2026-05-13 | -3.08 | -1.88 | +39.01% |
| 2026-03-12 | -2.99 | -2.94 | +1.59% |
| 2025-11-05 | -5.07 | -4.64 | +8.42% |
| 2025-08-07 | -4.75 | -5.44 | -14.61% |
| 2025-05-06 | -5.38 | -4.96 | +7.74% |
| 2025-03-06 | -5.79 | -5.12 | +11.52% |
| 2024-11-06 | -5.33 | -5.44 | -2.15% |
| 2024-08-13 | -5.84 | -5.28 | +9.59% |
| 2024-05-14 | -6.28 | -5.60 | +10.83% |
| 2024-03-19 | -11.26 | -11.04 | +1.99% |
| 2023-11-08 | -12.00 | -18.56 | -54.69% |
| 2023-08-09 | -6.81 | -12.00 | -76.24% |
| 2023-05-09 | -10.53 | -11.52 | -9.43% |
| 2023-03-15 | -8.10 | -11.52 | -42.17% |
| 2022-11-08 | -8.49 | -8.48 | +0.15% |